Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Proteasome Inhibitor
100%
Biological Activity
100%
Ixazomib
100%
Oral
100%
Checkpoint Kinase 2
37%
Antineoplastic Activity
25%
B Cell Lymphoma Cell
25%
In Vitro
12%
Protein P53
12%
Programmed Cell Death
12%
Xenograft
12%
DNA Damage Response
12%
Gamma Interferon
12%
Lymphoma Cell
12%
Molecular Pathology
12%
Diseases
12%
Xeno-transplant
12%
Diffuse Large B-Cell Lymphoma Cell Line
12%
Genetics
12%
Keyphrases
Protease Inhibitors
100%
Biological Effects
100%
Preclinical Evaluation
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Antitumor Activity
25%
Lymphoma Cells
25%
Pharmacological Inhibitors
12%
Mouse Model
12%
Effective Treatment
12%
Drug Concentration
12%
Poor Prognosis
12%
Apoptosis Induction
12%
Therapeutic Regimen
12%
Genetic Features
12%
In Vivo Model
12%
Interferon-γ
12%
Molecular Pathogenesis
12%
Relapsed Disease
12%
Immunoproteasome
12%
Lymphoma Patients
12%
DNA Damage Response Pathway
12%
Treatment-resistant
12%
Mutated p53
12%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
Proteasome Inhibitor
100%
Biological Activity
100%
Kinase
33%
Phosphotransferase
33%
Antineoplastic Activity
22%
Genetics
11%
P53
11%
Mouse Model
11%
DNA Damage Response
11%
Interferon Gamma
11%
Drug Concentration
11%
Programmed Cell Death
11%
Pharmacology, Toxicology and Pharmaceutical Science
Proteasome Inhibitor
100%
Diffuse Large B Cell Lymphoma
100%
Ixazomib
100%
Checkpoint Kinase 2
33%
Neoplasm
22%
Protein P53
11%
Mouse Model
11%
Drug Concentration
11%
Gamma Interferon
11%
Molecular Pathology
11%
Diseases
11%